for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Constellation Pharmaceuticals Inc

CNST.OQ

Latest Trade

37.60USD

Change

-0.08(-0.21%)

Volume

80,873

Today's Range

36.65

 - 

38.03

52 Week Range

6.09

 - 

59.14

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
37.68
Open
37.81
Volume
80,873
3M AVG Volume
11.55
Today's High
38.03
Today's Low
36.65
52 Week High
59.14
52 Week Low
6.09
Shares Out (MIL)
40.04
Market Cap (MIL)
1,508.55
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Constellation Pharmaceuticals Inc Earnings Release

Latest Developments

More

Constellation Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Constellation Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Constellation Pharmaceuticals Provides Updated Preliminary Data From Manifest Clinical Trial With CPI-0610 In Oral & Poster Presentations At Ash

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is primarily if focused on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression and drug resistance. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-1205, and the other program is evaluating a compound, CPI-0610.

Contact Info

215 1st St Ste 200

+1.617.7140555

https://www.constellationpharma.com/

Executive Leadership

Mark A. Goldsmith

Independent Chairman of the Board

Jigar Raythatha

President, Chief Executive Officer, Director

Emma Reeve

Chief Financial Officer, Senior Vice President, Treasurer

Adrian Senderowicz

Senior Vice President, Chief Medical Officer

Patrick Trojer

Chief Scientific Officer

Key Stats

1.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-5.000

2019(E)

-2.994
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
20.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
61.48
LT Debt To Equity (MRQ)
61.48
Return on Investment (TTM)
-77.34
Return on Equity (TTM)
-68.17

Latest News

Latest News

Biotechs dominate filing activity

Judging by recent filing activity, biotechs are again likely to represent a large proportion of IPO activity in July.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up